HR+/HER2- Metastatic Breast Cancer
1 clinical trials · Condition
◉ Watch HR+/HER2- Metastatic Breast Cancer
| Record | Firm | Date |
|---|---|---|
| Study of Sacituzumab Govitecan (SG) in Japanese Participants With Advanced Solid Tumors (NCT05101096) | Gilead Sciences | 2021-10-20 |
Track HR+/HER2- Metastatic Breast Cancer automatically
Every clearance here is in the API, with alerts when new ones post.